Europe Branded Generics Market
Taille du marché en milliards USD
TCAC :
% 
USD
67.97 Billion
USD
96.49 Billion
2024
2032
 Période de prévision |
2025 –2032 |
 Taille du marché (année de référence) |
USD 67.97 Billion |
 Taille du marché (année de prévision) |
USD 96.49 Billion |
 TCAC |
% |
| Principaux acteurs du marché |
|
Segmentation du marché européen des médicaments génériques de marque, par classe thérapeutique (antihypertenseurs, hormones, antimétabolites, hypolipémiants, antiépileptiques, agents alkylants, antidépresseurs, antipsychotiques, autres), par application (maladies cardiovasculaires, gestion de la douleur et anti-inflammatoires, oncologie, diabète, neurologie, maladies gastro-intestinales, dermatologie, autres), par voie d'administration (orale, injectable, topique, autres), par type de produit (médicaments génériques de marque à valeur ajoutée, génériques commerciaux), par tranche d'âge des patients (adultes, personnes âgées, enfants), par utilisateur final (hôpitaux, cliniques, soins à domicile, établissements d'enseignement et de recherche, autres), par canal de distribution (pharmacies de détail, pharmacies hospitalières, appels d'offres directs, autres) - Tendances du secteur et prévisions jusqu'en 2032
Taille du marché européen des médicaments génériques de marque
- Le marché européen des médicaments génériques de marque était évalué à 67,97 milliards de dollars en 2024 et devrait atteindre 96,49 milliards de dollars d'ici 2032.
- Au cours de la période de prévision allant de 2025 à 2032, le marché devrait croître à un TCAC de 4,5 %, principalement sous l'effet de l'augmentation des dépenses de santé, de la prévalence croissante des maladies chroniques et de la demande de médicaments abordables et de haute qualité, tant dans les pays développés que dans les pays émergents.
- Cette croissance est également alimentée par l'expiration des brevets des médicaments d'origine, les politiques gouvernementales favorisant les traitements abordables, l'amélioration de l'accès aux soins de santé dans les économies émergentes et l'adoption croissante des plateformes de santé numérique et de pharmacie en ligne. Les innovations continues dans les formulations médicamenteuses, l'amélioration des stratégies d'observance thérapeutique et l'élargissement des portefeuilles de génériques de marque par les principaux laboratoires pharmaceutiques devraient également accélérer la croissance du marché à l'échelle mondiale.
Analyse du marché européen des médicaments génériques de marque
- Le marché européen des médicaments génériques de marque connaît une forte croissance, portée par une demande croissante de produits pharmaceutiques de qualité à un prix abordable, alliant l'accessibilité des génériques à la notoriété des marques. Les médicaments génériques de marque jouent un rôle essentiel dans l'amélioration de l'observance thérapeutique, l'élargissement de l'accès aux médicaments essentiels et la création de nouvelles opportunités de revenus pour les entreprises pharmaceutiques, tant sur les marchés émergents que développés. Ce marché est confronté à des défis tels que les variations réglementaires entre les pays, les pressions sur les prix et la nécessité d'une innovation constante pour fidéliser la clientèle.
- Les segments de la prise en charge des maladies chroniques, de l'oncologie, des maladies cardiovasculaires et des maladies infectieuses constituent des moteurs de croissance essentiels. La prévalence croissante des maladies non transmissibles, la sensibilisation accrue aux soins de santé et l'accès élargi aux soins dans les économies émergentes stimulent la demande de médicaments génériques de marque. Par ailleurs, l'adoption croissante des biosimilaires et des génériques de spécialité influence la dynamique du marché, en offrant des alternatives aux médicaments originaux coûteux tout en préservant leur efficacité et leur innocuité. Les entreprises pharmaceutiques déploient des stratégies marketing, des actions d'information auprès des patients et des partenariats stratégiques pour favoriser l'adoption des médicaments génériques de marque.
- L'Allemagne domine le marché, suivie du Royaume-Uni et de l'Italie, grâce à ses capacités de production de médicaments génériques bien établies, à des politiques gouvernementales favorables et à l'augmentation des dépenses de santé. L'Amérique du Nord suit, portée par une forte demande de traitements pour les maladies chroniques, une couverture santé croissante et des réseaux de distribution performants. L'Europe affiche une croissance soutenue, favorisée par des politiques de substitution aux médicaments génériques, des mesures de maîtrise des coûts et une attention accrue portée à l'efficience des soins. Les marchés émergents d'Amérique latine, du Moyen-Orient et d'Afrique connaissent une adoption progressive grâce à l'amélioration des infrastructures de santé, à une harmonisation réglementaire accrue et au développement des capacités de production pharmaceutique.
- Le segment des antihypertenseurs devrait dominer le marché avec une part de marché de 22,51 %, grâce à la préférence des patients pour un dosage pratique, un bon rapport coût-efficacité et une large applicabilité dans divers domaines thérapeutiques.
Portée du rapport et segmentation du marché européen des médicaments génériques de marque
|
Attributs |
Aperçu du marché européen des médicaments génériques de marque |
|
Segments couverts |
|
|
Pays couverts |
Europe
|
|
Acteurs clés du marché |
|
|
Opportunités de marché |
|
|
Ensembles d'informations de données à valeur ajoutée |
En plus des informations sur les scénarios de marché tels que la valeur du marché, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché élaborés par Data Bridge Market Research comprennent également une analyse approfondie par des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire. |
Tendances du marché européen des médicaments génériques de marque
« La demande croissante de médicaments abordables et de haute qualité stimule la croissance du marché européen des génériques de marque »
- L'augmentation des coûts des soins de santé, le vieillissement de la population et la prévalence croissante des maladies chroniques et liées au mode de vie alimentent la demande européenne de médicaments abordables et de haute qualité, favorisant ainsi la croissance des génériques de marque. Ces derniers constituent une alternative économique aux médicaments de référence tout en maintenant des normes élevées d'efficacité et de sécurité, ce qui les rend essentiels sur les marchés développés comme émergents.
- Les gouvernements et les organismes payeurs de soins de santé encouragent activement l'utilisation des médicaments génériques de marque par le biais de politiques, de systèmes de remboursement et de programmes de substitution afin de maîtriser les dépenses de santé, d'élargir l'accès aux traitements et d'améliorer l'observance thérapeutique. Ces mesures stimulent l'adoption des médicaments génériques sur le marché dans de nombreux domaines thérapeutiques, notamment les maladies cardiovasculaires, le diabète, l'oncologie et les troubles du système nerveux central.
- Par exemple, en mars 2024, la FDA américaine a approuvé plusieurs nouvelles formulations génériques de marque pour des catégories thérapeutiques à forte demande telles que le diabète et l'hypertension, témoignant de l'activité croissante en matière de développement et du soutien réglementaire aux alternatives économiques aux médicaments de marque. Ceci illustre l'expansion continue du marché européen des génériques de marque en réponse aux besoins des patients et du système de santé.
- Les économies émergentes, notamment en Allemagne et en Amérique latine, connaissent une adoption accélérée des médicaments génériques de marque grâce au développement des infrastructures de santé, à la croissance des classes moyennes et aux initiatives gouvernementales visant à améliorer l'accès aux traitements. Les entreprises augmentent leur production locale, investissent dans la recherche et le développement et renforcent leurs réseaux de distribution pour répondre à la demande croissante dans ces régions.
- Alors que les systèmes de santé européens continuent de privilégier l'abordabilité, l'accessibilité et l'observance thérapeutique, le rôle des médicaments génériques de marque deviendra de plus en plus crucial pour garantir une offre de soins de santé durable tout en stimulant l'innovation dans la fabrication, le conditionnement et le développement de médicaments axés sur le patient.
Dynamique du marché européen des médicaments génériques de marque
Conducteur
« Expiration des brevets de médicaments à succès »
- L'expiration imminente des brevets de médicaments à succès figure parmi les principaux moteurs structurels de l'expansion du marché européen des génériques de marque. Lorsqu'un médicament innovant à fort chiffre d'affaires perd son exclusivité, cela ouvre la voie aux fabricants de génériques et de biosimilaires pour commercialiser des versions concurrentes, érodant ainsi la part de marché du médicament original et réorientant la demande vers des alternatives moins coûteuses.
- Ce « précipice des brevets » déclenche une cascade d'effets en aval : les fabricants se précipitent pour déposer des demandes abrégées de nouveaux médicaments (ANDA) ou des demandes de biosimilaires, les autorités réglementaires accélèrent l'examen, les payeurs privilégient de plus en plus les génériques et les patients ont accès à des génériques de marque plus abordables.
- Au cours de la dernière décennie, la perte d'exclusivité de nombreux médicaments a créé des opportunités récurrentes pour les fabricants de génériques établis et les nouveaux entrants, modifiant la dynamique des prix, favorisant la consolidation de la production de génériques et accélérant l'expansion géographique vers les marchés émergents. De fait, l'importance des revenus en jeu liés à l'expiration des brevets justifie souvent les investissements dans les génériques complexes et les biosimilaires.
- Surtout, le calendrier et la prévisibilité des expirations de brevets offrent aux entreprises de génériques des fenêtres de planification stratégique pour anticiper les lancements, investir dans le développement de nouveaux produits, nouer des alliances et pré-déposer les dossiers réglementaires avant la perte d'exclusivité.
- Par conséquent, le secteur des médicaments génériques de marque devient un moteur concurrentiel cyclique, intimement lié à l'expiration des brevets des médicaments à succès.
Retenue/Défi
« Litiges en matière de brevets et risques liés à la propriété intellectuelle »
- Les litiges en matière de brevets et les risques liés à la propriété intellectuelle constituent un frein important au marché européen des médicaments génériques de marque. La complexité et la durée de ces litiges peuvent retarder l'arrivée des génériques sur le marché, entravant la concurrence et maintenant des prix élevés.
- Ces batailles juridiques impliquent souvent plusieurs niveaux de revendications de brevets, notamment des brevets de méthode d'utilisation et des brevets secondaires, qui peuvent prolonger la période d'exclusivité des médicaments de marque au-delà de l'expiration de leur brevet initial.
- De plus, le fardeau financier que représentent les poursuites pour contrefaçon de brevets peut dissuader les fabricants de génériques, notamment les petites entreprises, d'entrer sur le marché. L'évolution constante du droit des brevets et l'utilisation stratégique des portefeuilles de brevets par les entreprises pionnières complexifient davantage la dynamique du marché, pouvant mener à un marché mondial des médicaments de marque et des génériques.
- Par exemple, en octobre 2025, le journal The Economic Times a rapporté que la société Natco Pharma, basée à Hyderabad, avait remporté un litige de brevets contre le groupe pharmaceutique suisse Roche concernant le risdiplam, un médicament utilisé pour traiter l'amyotrophie spinale.
- Ces obstacles juridiques et financiers affectent à la fois la rentabilité des fabricants et l'accès des patients à des médicaments abordables. Globalement, les litiges en matière de brevets et les risques liés à la propriété intellectuelle demeurent des freins majeurs à la concurrence et à la croissance sur le marché européen des médicaments génériques de marque.
Étendue du marché des médicaments génériques de marque en Europe
Le marché européen des médicaments génériques de marque est segmenté en sept segments importants qui sont basés sur la classe de médicament, l'application, la voie d'administration, le type de produit, les données démographiques des patients, l'utilisateur final et le canal de distribution.
• Par classe de médicament
Le marché européen des médicaments génériques de marque est segmenté, par classe thérapeutique, en antihypertenseurs, hormones, antimétabolites, hypolipémiants, antiépileptiques, agents alkylants, antidépresseurs, antipsychotiques et autres. En 2025, le segment des antihypertenseurs devrait dominer le marché avec une part de 22,51 %, sous l'effet de la prévalence croissante des maladies cardiovasculaires à l'échelle mondiale, d'une meilleure sensibilisation à la prise en charge de l'hypertension et d'une préférence grandissante des patients et des professionnels de santé pour des alternatives génériques plus économiques.
Le segment des antihypertenseurs devrait connaître une croissance annuelle composée de 7,0 % au cours de la période de prévision allant de 2025 à 2032, grâce à l'innovation continue dans les thérapies combinées à dose fixe, aux initiatives gouvernementales promouvant des médicaments abordables et à l'élargissement de l'accès aux soins de santé dans les économies émergentes, qui, collectivement, stimulent l'adoption des génériques de marque antihypertenseurs.
• Sur demande
En fonction de l'application, le marché est segmenté en maladies cardiovasculaires, gestion de la douleur et anti-inflammatoires, oncologie, diabète, neurologie, maladies gastro-intestinales, dermatologie et autres. En 2025, le segment des maladies cardiovasculaires devrait dominer le marché avec une part de 29,30 %, en raison de la prévalence croissante des troubles cardiaques à l'échelle mondiale, du vieillissement de la population et d'une sensibilisation accrue à la prévention cardiovasculaire, conjuguée à la disponibilité de médicaments génériques de marque à un coût abordable.
Le segment des maladies cardiovasculaires devrait connaître une croissance régulière avec un TCAC de 5,9 %, grâce à l'amélioration de l'accès aux médicaments essentiels dans les systèmes de santé des marchés émergents, à la popularité croissante des thérapies combinées à dose fixe et aux efforts continus de recherche et développement qui améliorent l'efficacité et le profil de sécurité des médicaments génériques de marque pour le traitement des maladies cardiovasculaires.
• Par voie d'administration
Selon la voie d'administration, le marché européen des médicaments génériques de marque est segmenté en administration orale, injectable, topique et autres. En 2025, le segment oral devrait dominer le marché avec une part de 55,87 %, grâce à sa facilité d'administration, à une bonne observance thérapeutique, à la large disponibilité des formulations orales et à son rapport coût-efficacité par rapport aux autres voies.
Le segment oral devrait connaître une croissance accélérée de 4,7 % au cours de la période prévisionnelle, soutenue par la prévalence croissante des maladies chroniques nécessitant un traitement médicamenteux à long terme, la préférence croissante pour les thérapies auto-administrées et l'introduction continue de formulations orales innovantes avec une biodisponibilité améliorée et des conceptions conviviales pour les patients.
• Par type de produit
Selon le type de produit, le marché est segmenté en génériques de marque à valeur ajoutée et en génériques commercialisés sous des noms commerciaux. En 2025, le segment des génériques de marque à valeur ajoutée devrait dominer le marché avec une part de 66,87 %, grâce à leur efficacité accrue, leur profil de sécurité amélioré, leurs formulations adaptées aux patients et leur capacité à offrir des avantages thérapeutiques différenciés par rapport aux génériques standards.
Le segment des médicaments génériques de marque à valeur ajoutée gagne en importance et connaît une croissance annuelle composée de 4,6 % en raison de la préférence croissante des prestataires de soins de santé pour les formulations qui améliorent l'observance du traitement par le patient, de la demande croissante de thérapies combinées, de l'innovation continue dans les technologies d'administration de médicaments et de l'accent mis sur la satisfaction des besoins médicaux non satisfaits dans les traitements des maladies chroniques et complexes.
• Selon les caractéristiques démographiques des patients
En fonction des caractéristiques démographiques des patients, le marché est segmenté en adultes, personnes âgées et enfants. En 2025, le segment des adultes devrait dominer le marché avec une part de 65,13 %, en raison de la prévalence plus élevée de maladies chroniques et liées au mode de vie, telles que les troubles cardiovasculaires, le diabète et l'hypertension, au sein de cette population, ce qui génère une demande constante de médicaments génériques de marque.
Le segment des adultes devrait croître à un TCAC de 4,6 %, sous l'effet d'une sensibilisation accrue aux soins de santé, d'un accès facilité aux médicaments abordables, de la croissance de la classe moyenne dans les économies émergentes et de la préférence pour les génériques de marque à valeur ajoutée qui offrent une meilleure efficacité et une meilleure observance chez les patients adultes.
• Par l'utilisateur final
En fonction de l'utilisateur final, le marché est segmenté en hôpitaux, cliniques, soins à domicile, établissements d'enseignement et de recherche, et autres. En 2025, le segment des hôpitaux devrait dominer le marché avec une part de 51,52 %, grâce au volume élevé de traitements, à la préférence pour les médicaments de marque et les génériques de haute qualité pour les soins intensifs, et aux pratiques d'approvisionnement centralisées des hôpitaux qui garantissent un approvisionnement constant en médicaments essentiels.
Le segment des hôpitaux devrait enregistrer la croissance la plus rapide, soit 4,8 %, entre 2025 et 2032, grâce à l'expansion des infrastructures hospitalières, au nombre croissant d'hôpitaux spécialisés et multiservices, à la hausse des admissions à l'hôpital pour des affections chroniques et aiguës, et à l'adoption croissante de médicaments génériques de marque à valeur ajoutée dans les soins aux patients hospitalisés pour de meilleurs résultats thérapeutiques.
• Par canal de distribution
En fonction du canal de distribution, le marché est segmenté en pharmacies de détail, pharmacies hospitalières, appels d'offres directs et autres. En 2025, le segment des pharmacies de détail devrait dominer le marché avec une part de 52,52 %, grâce à la large disponibilité des médicaments génériques de marque dans les points de vente, à la préférence des consommateurs pour un accès facile aux médicaments et à la forte présence des chaînes de pharmacies et des pharmacies indépendantes dans les zones urbaines et périurbaines.
Le segment des pharmacies de détail devrait enregistrer la croissance la plus rapide, soit 4,7 %, entre 2025 et 2032, sous l'impulsion de la hausse de l'automédication, de la sensibilisation croissante aux médicaments génériques de marque à prix abordable, de l'expansion des réseaux de pharmacies et des initiatives gouvernementales favorisant un accès abordable aux médicaments essentiels par le biais des circuits de distribution.
Marché européen des médicaments génériques de marque – Analyse régionale
- L'Allemagne devrait dominer le marché européen des médicaments génériques de marque avec la plus grande part de revenus (18,75 %) en 2025, grâce à une forte demande de produits pharmaceutiques abordables et de haute qualité et à l'augmentation des dépenses de santé dans toute la région.
- Cette expansion est alimentée par le soutien croissant des gouvernements aux infrastructures de santé, la prévalence croissante des maladies chroniques et la sensibilisation accrue à l'observance thérapeutique, autant de facteurs qui favorisent l'adoption des médicaments génériques de marque.
- Des pays comme l'Allemagne et la France sont à la pointe de la région grâce à leurs capacités de production pharmaceutique bien établies, leur soutien réglementaire aux médicaments génériques et leurs investissements croissants dans la production nationale de soins de santé.
- De plus, des politiques favorables encourageant la production locale de médicaments, l'accès aux soins de santé et les exportations pharmaceutiques accélèrent encore la croissance du marché en Allemagne.
Analyse du marché européen des médicaments génériques de marque
L'Europe conserve une place prépondérante sur le marché européen des médicaments génériques de marque, grâce à ses systèmes de santé performants, ses politiques de substitution par les génériques et sa volonté de maîtriser les coûts. Des économies clés comme l'Allemagne, la France, l'Italie et le Royaume-Uni dominent ce marché grâce à un accès élevé aux soins, une adoption croissante des génériques de spécialité et des investissements dans la prise en charge des maladies chroniques. Le soutien réglementaire aux médicaments génériques, conjugué à une attention accrue portée au vieillissement de la population et à la demande croissante de traitements abordables, contribue également à la croissance du marché. La collaboration continue entre les fabricants de produits pharmaceutiques, les instituts de recherche et les professionnels de santé garantit une innovation constante et une distribution efficace des médicaments génériques de marque sur l'ensemble du continent.
Analyse du marché des médicaments génériques de marque en France et en Europe
La France occupe une place importante sur le marché européen des médicaments génériques de marque, grâce à son système de santé performant, ses capacités de production pharmaceutique de pointe et les initiatives gouvernementales encourageant la fabrication nationale de médicaments. L'accent mis par le pays sur la prise en charge des maladies chroniques, l'oncologie et les thérapies cardiovasculaires stimule la demande de médicaments génériques de marque. Par ailleurs, les partenariats stratégiques entre les entreprises pharmaceutiques et les instituts de recherche favorisent l'innovation dans le domaine des médicaments génériques à forte valeur ajoutée et des thérapies de spécialité. L'importance croissante accordée par la France à l'accès aux soins, à leur abordabilité et à l'observance thérapeutique renforce encore son rôle majeur dans le paysage pharmaceutique européen.
Analyse du marché des médicaments génériques de marque en Espagne et en Europe
L'Espagne s'impose comme un marché en pleine croissance au sein de l'industrie européenne des médicaments génériques de marque, portée par l'extension de la couverture santé, la demande croissante de traitements abordables et l'adoption grandissante de solutions de gestion des maladies chroniques. L'accent mis par le pays sur la modernisation du système de santé, les initiatives de santé numérique et la production pharmaceutique régionale a accéléré l'utilisation des médicaments génériques de marque. Par ailleurs, les collaborations entre les fabricants locaux, les instituts de recherche et les entreprises pharmaceutiques internationales favorisent l'innovation et la commercialisation de médicaments génériques de haute qualité. Les investissements espagnols dans les infrastructures de santé et les campagnes de sensibilisation des patients contribuent à une croissance soutenue du marché.
Analyse du marché des médicaments génériques de marque en Allemagne et en Europe
L'Allemagne devrait enregistrer le taux de croissance annuel composé (TCAC) le plus élevé au cours de la période de prévision, grâce à la hausse des dépenses de santé, à l'industrialisation rapide de la production pharmaceutique et à la prévalence croissante des maladies chroniques et liées au mode de vie. Des pays comme l'Inde, la Chine et le Japon sont les moteurs de cette croissance, portés par l'expansion de leurs capacités de production nationales, la fabrication de médicaments à moindre coût et des politiques réglementaires favorables. Les solides capacités d'exportation pharmaceutique de la région, l'accès croissant aux soins de santé et les initiatives en faveur de la production locale de médicaments accélèrent encore la croissance du marché. La sensibilisation accrue à l'observance thérapeutique et la demande de médicaments de qualité et abordables continuent de renforcer la position dominante de la région sur le marché européen.
Les principaux acteurs du marché sont :
- Teva Pharmaceutical Industries Ltd. (Israël)
- Viatris Inc. (États-Unis)
- Groupe Sandoz AG (Suisse)
- Laboratoires Dr. Reddy's Ltd. (Inde)
- Sun Pharmaceutical Industries Ltd. (Inde)
- Aurobindo Pharma (Inde)
- Cipla Pharmaceuticals (Inde)
- Fresenius Kabi (Allemagne)
- Abbott (États-Unis)
- Glenmark Pharmaceuticals (Inde)
- Hikma Pharmaceuticals PLC (Royaume-Uni)
- Lupin Pharmaceuticals (Inde)
- Emcure Pharmaceuticals (Inde)
- Bausch Health Companies Inc. (Canada)
- Mankind Pharma (Inde)
- Jubilant Pharma (Inde)
- Natco Pharma (Inde)
- ARISTO Pharmaceuticals Private Limited (Inde)
- Biocon Limited (Inde)
- Torrent Pharmaceuticals Ltd. (Inde)
- Endo, Inc. (États-Unis)
- Alembic Pharmaceuticals Limited (Inde)
- SAGENT Pharmaceuticals (États-Unis)
- Panacea Biotec (Inde)
Dernières évolutions du marché européen des médicaments génériques de marque
- En octobre 2025, la FDA américaine a approuvé une indication élargie pour UZEDY (rispéridone) suspension injectable à libération prolongée. Ce médicament est désormais approuvé pour le traitement de la schizophrénie chez les enfants et les adolescents âgés de 13 à 17 ans, en plus des adultes. Il offre ainsi une option de traitement à action prolongée aux jeunes patients atteints de cette maladie chronique.
- En août 2025, Teva a obtenu l'approbation de la FDA américaine et a lancé la première version générique de Saxenda (liraglutide) injectable. Cet agoniste générique des récepteurs du GLP-1 est approuvé comme traitement de l'obésité chez l'adulte et l'enfant, offrant ainsi une option plus accessible pour la gestion du poids à long terme.
- En août 2025, Viatris a obtenu l'autorisation de la FDA américaine pour la première version générique de l'injection de saccharose de fer, un médicament utilisé pour traiter l'anémie ferriprive. Cette avancée offre une option de traitement plus abordable aux patients et aux professionnels de santé aux États-Unis. Cette autorisation renforce le portefeuille de médicaments injectables génériques de Viatris et améliore l'accès des patients à ce traitement essentiel.
- En avril 2025, Viatris a déposé des demandes d'autorisation de mise sur le marché complémentaires auprès du ministère japonais de la Santé, du Travail et des Affaires sociales pour l'EFFEXOR (venlafaxine) dans le traitement du trouble d'anxiété généralisée. Cette démarche réglementaire vise à étendre l'utilisation thérapeutique de ce médicament sur le marché japonais. S'il est approuvé, il offrira une nouvelle option de traitement aux patients japonais souffrant de cette affection.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE BRANDED GENERICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER'S FIVE FORCES ANALYSIS
4.2 BRAND OUTLOOK
4.2.1 PRODUCT VS BRAND OVERVIEW
4.2.1.1 PRODUCT OVERVIEW
4.2.1.2 BRAND OVERVIEW
4.3 CONSUMER BUYING BEHAVIOUR – EUROPE BRANDED GENERICS MARKET
4.4 INNOVATION TRACKER AND STRATEGIC ANALYSIS
4.4.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
4.4.1.1 JOINT VENTURES
4.4.1.2 MERGERS AND ACQUISITIONS
4.4.1.3 LICENSING AND PARTNERSHIP
4.4.1.4 TECHNOLOGY COLLABORATIONS
4.4.1.5 STRATEGIC DIVESTMENTS
4.4.2 NUMBER OF PRODUCTS IN DEVELOPMENT
4.4.3 STAGE OF DEVELOPMENT
4.4.4 TIMELINES AND MILESTONES
4.4.5 INNOVATION STRATEGIES AND METHODOLOGIES
4.4.6 RISK ASSESSMENT AND MITIGATION
4.4.7 FUTURE OUTLOOK
4.5 PATENT ANALYSIS – EUROPE BRANDED GENERICS MARKET
4.5.1 PATENT QUALITY AND STRENGTH
4.5.2 PATENT FAMILIES
4.5.3 LICENSING AND COLLABORATIONS
4.5.4 REGIONAL PATENT LANDSCAPE
4.5.5 IP STRATEGY AND MANAGEMENT
4.6 PRICING ANALYSIS
4.7 VALUE CHAIN ANALYSIS
4.7.1 OVERVIEW
4.7.2 RAW MATERIAL SUPPLY
4.7.3 COMPONENT MANUFACTURING AND PROCESSING
4.7.4 EQUIPMENT AND TECHNOLOGY PROVIDERS
4.7.5 DISTRIBUTION AND LOGISTICS
4.7.6 END-USERS (BRANDS & INDUSTRY SECTORS)
4.7.7 CONCLUSION
5 REGULATION COVERAGE
5.1 REGULATION COVERAGE (NORTH AMERICA)
5.2 REGULATION COVERAGE (SOUTH AMERICA)
5.3 REGULATION COVERAGE (EUROPE)
5.4 REGULATION COVERAGE (MIDDLE EAST & AFRICA)
5.5 REGULATION COVERAGE (ASIA-PACIFIC)
5.6 SUPPLY CHAIN ANALYSIS OF EUROPE BRANDED GENERICS MARKET
5.6.1 OVERVIEW
5.6.2 LOGISTIC COST SCENARIO
5.6.3 IMPORTANCE OF LOGISTICS SERVICE PROVIDERS
5.6.4 CONCLUSION
5.7 TECHNOLOGICAL ADVANCEMENTS– EUROPE BRANDED GENERICS MARKET
5.7.1 ADVANCED FORMULATION TECHNOLOGIES
5.7.2 CONTINUOUS MANUFACTURING AND PROCESS OPTIMIZATION
5.7.3 ANTI-COUNTERFEITING AND SMART PACKAGING TECHNOLOGIES
5.7.4 MODIFIED DRUG DELIVERY SYSTEMS
5.7.5 DIGITAL TRANSFORMATION AND E-PRESCRIPTION INTEGRATION
5.7.6 ADVANCED ANALYTICAL AND QUALITY ASSURANCE TOOLS
5.7.7 PERSONALIZED GENERIC THERAPY DEVELOPMENT
5.7.8 SUSTAINABILITY AND ECO-FRIENDLY MANUFACTURING
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 PATENT EXPIRATIONS OF BLOCKBUSTER DRUGS
6.1.2 RISING PREVALENCE OF CHRONIC DISEASES
6.1.3 COST-EFFECTIVE ALTERNATIVE TO INNOVATOR DRUGS
6.1.4 SIMPLIFIED APPROVAL PATHWAYS FOR BRANDED GENERICS
6.2 RESTRAINS
6.2.1 PATENT LITIGATION AND INTELLECTUAL PROPERTY RISKS
6.2.2 COUNTERFEIT AND SUBSTANDARD DRUGS
6.3 OPPORTUNITIES
6.3.1 EXPANSION OF BRANDED GENERIC DRUG IN EMERGING MARKETS
6.3.2 PATENT CLIFF OF MAJOR DRUGS
6.3.3 EXPANSION INTO SPECIALTY AND COMPLEX GENERICS
6.4 CHALLENGES
6.4.1 INTENSE PRICE PRESSURE AMONG COMPETITORS
6.4.2 QUALITY PERCEPTION & PHYSICIAN/PATIENT TRUST IN BRANDED GENERIC DRUG
7 EUROPE BRANDED GENERIC MARKET, BY DRUG CLASS
7.1 OVERVIEW
7.2 ANTI-HYPERTENSIVE
7.2.1 DIURETICS
7.2.2 CE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS)
7.2.3 ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS)
7.2.4 BETA BLOCKERS (BBS)
7.2.5 CALCIUM CHANNEL BLOCKERS (CCBS)
7.2.6 DIRECT VASODILATORS
7.2.7 ALPHA-1 BLOCKERS
7.2.8 CENTRAL ALPHA-2 AGONISTS
7.2.9 HORMONES
7.2.10 STEROID HORMONES
7.2.11 SEX HORMONES
7.2.12 ESTROGENS
7.2.13 PROGESTOGENS
7.2.14 ANDROGENS
7.2.15 THYROID HORMONES
7.2.16 OTHER HORMONES
7.3 ANTIMETABOLITES
7.3.1 PURINE ANALOGUES
7.3.2 PYRIMIDINE ANALOGUES
7.3.3 FOLATE ANTAGONISTS
7.4 LIPID LOWERING DRUGS
7.4.1 STATINS (HMG-COA REDUCTASE INHIBITORS)
7.4.2 COMBINATION PRODUCTS AND OTHER AGENTS
7.4.3 FIBRATES
7.4.4 BILE ACID SEQUESTRANTS
7.4.5 PCSK9 INHIBITORS
7.5 ANTI-EPILEPTICS
7.6 ALKYLATING AGENTS
7.6.1 NITROGEN MUSTARDS
7.6.2 NITROSOUREAS
7.6.3 ALKYL SULFONATES
7.6.4 TRIAZENES
7.6.5 ETHYLENIMINES
7.7 ANTI-DEPRESSANTS
7.7.1 SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)
7.7.2 SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS)
7.7.3 TRICYCLIC ANTIDEPRESSANTS (TCAS)
7.7.4 ATYPICAL ANTIDEPRESSANTS
7.7.5 MONOAMINE OXIDASE INHIBITORS (MAOIS)
7.7.6 NMDA RECEPTOR ANTAGONISTS
7.8 ANTI-PSYCHOTICS
7.8.1 SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS
7.8.2 FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS
7.8.3 PHENOTHIAZINES
7.8.4 THIOXANTHENES
7.8.5 NEXT-GENERATION ANTIPSYCHOTICS
7.9 OTHERS
8 EUROPE BRANDED GENERICS MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 CARDIOVASCULAR DISEASES
8.3 PAIN MANAGEMENT AND ANTI-INFLAMMATORY
8.4 ONCOLOGY
8.5 DIABETES
8.6 NEUROLOGY
8.7 GASTROINTESTINAL DISEASES
8.8 DERMATOLOGY
8.9 OTHERS
9 EUROPE BRANDED GENERIC MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 ORAL
9.3 INJECTABLEA
9.4 TOPICAL ADMINISTRATION
9.5 OTHERS
10 EUROPE BRANDED GENERICS MARKET, BY PRODUCT TYPE
10.1 OVERVIEW
10.2 VALUE-ADDED BRANDED GENERICS
10.3 TRADE NAMED GENERICS
11 EUROPE BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS
11.1 OVERVIEW
11.2 ADULT
11.3 GERIATRIC
11.4 PEDIATRIC
12 EUROPE BRANDED GENERICS MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 CLINICS
12.4 HOMECARE
12.5 ACADEMIC & RESEARCH INSTITUTES
12.6 OTHERS
13 EUROPE BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 RETAIL PHARMACIES
13.3 HOSPITAL PHARMACIES
13.4 DIRECT TENDERS
13.5 OTHERS
14 EUROPE SHIP REPAIR AND MAINTENANCE SERVICES MARKET, BY REGION
14.1 EUROPE
14.1.1 GERMANY
14.1.2 UNITED KINGDOM
14.1.3 ITALY
14.1.4 FRANCE
14.1.5 SPAIN
14.1.6 TURKEY
14.1.7 RUSSIA
14.1.8 SWITZERLAND
14.1.9 NETHERLANDS
14.1.10 BELGIUM
14.1.11 SWEDEN
14.1.12 DENMARK
14.1.13 NORWAY
14.1.14 FINLAND
14.1.15 REST OF EUROPE
15 EUROPE BRANDED GENERICS MARKET: COMPANY LANDSCAPE
15.1 MANUFACTURER COMPANY SHARE ANALYSIS: EUROPE
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 TEVA PHARMACEUTICAL INDUSTRIES LTD.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 VIATRIS INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 SANDOZ GROUP AG
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 DR.REDDY’S LABORATORIES LTD.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS
17.5 SUN PHARMACEUTICAL INDUSTRIES LTD.
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.6 ABBOTT
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENTS
17.7 ALEMBIC PHARMACEUTICALS LIMITED
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 AMNEAL PHARMACEUTICALS LLC.
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 ARISTO PHARMACEUTICALS PRIVATE LIMITED
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 ASPEN HOLDINGS
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 AUROBINDO PHARMA USA (SUBSIDIARY OF AUROBINDO PHARMA LIMITED)
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENTS
17.12 BAUSCH HEALTH COMPANIES INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENT
17.13 BIOCON.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENTS
17.14 CIPLA
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENTS
17.15 EMCURE PHARMACEUTICALS LIMITED
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENTS
17.16 ENDO, INC.
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
17.17 FRESENIUS SE & CO. KGAA
17.17.1 COMPANY SNAPSHOT
17.17.2 REVENUE ANALYSIS
17.17.3 PRODUCT PORTFOLIO
17.17.4 RECENT DEVELOPMENT
17.18 GLENMARK PHARMACEUTICALS LTD.
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENTS
17.19 HIKMA PHARMACEUTICALS PLC
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENTS
17.2 INTAS PHARMACEUTICALS LTD.
17.20.1 COMPANY SNAPSHOT
17.20.2 PRODUCT PORTFOLIO
17.20.3 RECENT DEVELOPMENTS
17.21 JUBILANT GENERICS LIMITED (SUBSIDIARY OF JUBILANT PHARMA COMPANY)
17.21.1 COMPANY SNAPSHOT
17.21.2 PRODUCT PORTFOLIO
17.21.3 RECENT DEVELOPMENTS
17.22 LUPIN
17.22.1 COMPANY SNAPSHOT
17.22.2 REVENUE ANALYSIS
17.22.3 PRODUCT PORTFOLIO
17.22.4 RECENT DEVELOPMENTS
17.23 MANKIND PHARMA LIMITED
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENTS
17.24 NATCO PHARMA LIMITED
17.24.1 COMPANY SNAPSHOT
17.24.2 REVENUE ANALYSIS
17.24.3 PRODUCT PORTFOLIO
17.24.4 RECENT DEVELOPMENTS
17.25 NEULAND LABORATORIES LTD.
17.25.1 COMPANY SNAPSHOT
17.25.2 REVENUE ANALYSIS
17.25.3 PRODUCT PORTFOLIO
17.25.4 RECENT DEVELOPMENT
17.26 ORCHIDPHARMA LTD.
17.26.1 COMPANY SNAPSHOT
17.26.2 REVENUE ANALYSIS
17.26.3 PRODUCT PORTFOLIO
17.26.4 RECENT DEVELOPMENT
17.27 PANACEA BIOTEC
17.27.1 COMPANY SNAPSHOT
17.27.2 REVENUE ANALYSIS
17.27.3 PRODUCT PORTFOLIO
17.27.4 RECENT DEVELOPMENT
17.28 SAGENT
17.28.1 COMPANY SNAPSHOT
17.28.2 PRODUCT PORTFOLIO
17.28.3 RECENT DEVELOPMENT
17.29 STRIDES PHARMA SCIENCE LIMITED.
17.29.1 COMPANY SNAPSHOT
17.29.2 REVENUE ANALYSIS
17.29.3 PRODUCT PORTFOLIO
17.29.4 RECENT DEVELOPMENT
17.3 TORRENT PHARMACEUTICALS LTD.
17.30.1 COMPANY SNAPSHOT
17.30.2 REVENUE ANALYSIS
17.30.3 PRODUCT PORTFOLIO
17.30.4 RECENT DEVELOPMENTS
17.31 USV PRIVATE LIMITED.
17.31.1 COMPANY SNAPSHOT
17.31.2 SERVICE PORTFOLIO
17.31.3 RECENT DEVELOPMENT
17.32 WOCKHARDT LIMITED
17.32.1 COMPANY SNAPSHOT
17.32.2 REVENUE ANALYSIS
17.32.3 PRODUCT PORTFOLIO
17.32.4 RECENT DEVELOPMENT
17.33 MCKESSON CORPORATION
17.33.1 COMPANY SNAPSHOT
17.33.2 REVENUE ANALYSIS
17.33.3 PRODUCT PORTFOLIO
17.33.4 RECENT DEVELOPMENT
17.34 CENCORA, INC.
17.34.1 COMPANY SNAPSHOT
17.34.2 REVENUE ANALYSIS
17.34.3 PRODUCT PORTFOLIO
17.34.4 RECENT DEVELOPMENT
17.35 CARDINAL HEALTH
17.35.1 COMPANY SNAPSHOT
17.35.2 REVENUE ANALYSIS
17.35.3 PRODUCT PORTFOLIO
17.35.4 RECENT DEVELOPMENT
17.36 ALVOGEN
17.36.1 COMPANY SNAPSHOT
17.36.2 SERVICE PORTFOLIO
17.36.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
Liste des tableaux
TABLE 1 BRAND COMPARATIVE ANALYSIS OF THE EUROPE BRANDED GENERICS MARKET
TABLE 2 PATENT LANDSCAPE
TABLE 3 EUROPE BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 4 EUROPE ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 5 EUROPE ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 6 EUROPE DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 7 EUROPE ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 8 EUROPE ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 9 EUROPE BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 10 EUROPE CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 11 EUROPE DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 12 EUROPE ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 13 EUROPE CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 14 EUROPE HORMONES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 15 EUROPE HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 16 EUROPE STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 17 EUROPE SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 18 EUROPE ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 19 EUROPE PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 20 EUROPE ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 21 EUROPE THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 22 EUROPE OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 23 EUROPE ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 24 EUROPE ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 25 EUROPE PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 26 EUROPE PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 27 EUROPE FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 28 EUROPE LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 29 EUROPE LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 30 EUROPE STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 31 EUROPE COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 32 EUROPE FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 33 EUROPE BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 34 EUROPE PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 35 EUROPE ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 36 EUROPE ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 37 EUROPE ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 38 EUROPE ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 39 EUROPE NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 40 EUROPE NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 41 EUROPE ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 42 EUROPE TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 43 EUROPE ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 44 EUROPE ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 45 EUROPE ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 46 EUROPE SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 47 EUROPE SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 48 EUROPE TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 49 EUROPE ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 50 EUROPE MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 51 EUROPE NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 52 EUROPE ANTI-PSYCHOTICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 53 EUROPE ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 54 EUROPE SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 55 EUROPE FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 56 EUROPE PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 57 EUROPE THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 58 EUROPE NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 59 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 60 EUROPE BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 61 EUROPE CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 62 EUROPE CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 63 EUROPE PAIN MANAGEMENT AND ANTI-INFLAMMATORY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 64 EUROPE PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 65 EUROPE ONCOLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 66 EUROPE ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 EUROPE SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 EUROPE HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 69 EUROPE DIABETES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 70 EUROPE DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 71 EUROPE NEUROLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 72 EUROPE NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 73 EUROPE GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 74 EUROPE GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 75 EUROPE DERMATOLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 76 EUROPE DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 78 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 79 EUROPE BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 80 EUROPE ORAL IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 81 EUROPE ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 EUROPE INJECTABLE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 83 EUROPE INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 84 EUROPE TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 85 EUROPE TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 86 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 87 EUROPE BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 88 EUROPE VALUE-ADDED BRANDED GENERICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 89 EUROPE TRADE NAMED GENERICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 90 EUROPE BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 91 EUROPE ADULT IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 92 EUROPE GERIATRIC IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 93 EUROPE PEDIATRIC IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 94 EUROPE BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 95 EUROPE HOSPITALS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 96 EUROPE CLINICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 97 EUROPE HOMECARE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 98 EUROPE ACADEMIC & RESEARCH INSTITUTES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 99 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 100 EUROPE BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 101 EUROPE RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 102 EUROPE RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 103 EUROPE HOSPITAL PHARMACIES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 104 EUROPE DIRECT TENDERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 105 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 106 EUROPE BRANDED GENERICS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 107 EUROPE BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 108 EUROPE ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 109 EUROPE DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 110 EUROPE ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 111 EUROPE ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 112 EUROPE BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 113 EUROPE CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 114 EUROPE DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 115 EUROPE ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 116 EUROPE CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 117 EUROPE HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 118 EUROPE STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 119 EUROPE SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 120 EUROPE ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 121 EUROPE PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 122 EUROPE ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 123 EUROPE THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 124 EUROPE OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 125 EUROPE ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 126 EUROPE PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 127 EUROPE PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 128 EUROPE FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 129 EUROPE LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 130 EUROPE STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 131 EUROPE COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 132 EUROPE FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 133 EUROPE BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 134 EUROPE PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 135 EUROPE ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 136 EUROPE ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 137 EUROPE NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 138 EUROPE NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 139 EUROPE ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 140 EUROPE TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 141 EUROPE ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 142 EUROPE ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 143 EUROPE SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 144 EUROPE SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 145 EUROPE TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 146 EUROPE ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 147 EUROPE MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 148 EUROPE NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 149 EUROPE ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 150 EUROPE SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 151 EUROPE FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 152 EUROPE PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 153 EUROPE THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 154 EUROPE NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 155 EUROPE BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 156 EUROPE CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 157 EUROPE PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 158 EUROPE ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 159 EUROPE SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 160 EUROPE HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 161 EUROPE DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 162 EUROPE NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 163 EUROPE GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 164 EUROPE DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 165 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 166 EUROPE BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 167 EUROPE ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 168 EUROPE INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 169 EUROPE TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 170 EUROPE BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 171 EUROPE BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 172 EUROPE BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 173 EUROPE BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 174 EUROPE RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 175 GERMANY BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 176 GERMANY ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 177 GERMANY DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 178 GERMANY ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 179 GERMANY ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 180 GERMANY BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 181 GERMANY CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 182 GERMANY DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 183 GERMANY ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 184 GERMANY CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 185 GERMANY HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 186 GERMANY STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 187 GERMANY SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 188 GERMANY ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 189 GERMANY PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 190 GERMANY ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 191 GERMANY THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 192 GERMANY OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 193 GERMANY ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 194 GERMANY PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 195 GERMANY PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 196 GERMANY FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 197 GERMANY LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 198 GERMANY STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 199 GERMANY COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 200 GERMANY FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 201 GERMANY BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 202 GERMANY PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 203 GERMANY ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 204 GERMANY ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 205 GERMANY NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 206 GERMANY NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 207 GERMANY ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 208 GERMANY TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 209 GERMANY ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 210 GERMANY ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 211 GERMANY SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 212 GERMANY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 213 GERMANY TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 214 GERMANY ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 215 GERMANY MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 216 GERMANY NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 217 GERMANY ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 218 GERMANY SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 219 GERMANY FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 220 GERMANY PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 221 GERMANY THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 222 GERMANY NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 223 GERMANY BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 224 GERMANY CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 225 GERMANY PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 226 GERMANY ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 227 GERMANY SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 228 GERMANY HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 229 GERMANY DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 230 GERMANY NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 231 GERMANY GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 232 GERMANY DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 233 GERMANY OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 234 GERMANY BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 235 GERMANY ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 236 GERMANY INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 237 GERMANY TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 238 GERMANY BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 239 GERMANY BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 240 GERMANY BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 241 GERMANY BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 242 GERMANY RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 243 UNITED KINGDOM BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 244 UNITED KINGDOM ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 245 UNITED KINGDOM DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 246 UNITED KINGDOM ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 247 UNITED KINGDOM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 248 UNITED KINGDOM BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 249 UNITED KINGDOM CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 250 UNITED KINGDOM DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 251 UNITED KINGDOM ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 252 UNITED KINGDOM CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 253 UNITED KINGDOM HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 254 UNITED KINGDOM STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 255 UNITED KINGDOM SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 256 UNITED KINGDOM ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 257 UNITED KINGDOM PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 258 UNITED KINGDOM ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 259 UNITED KINGDOM THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 260 UNITED KINGDOM OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 261 UNITED KINGDOM ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 262 UNITED KINGDOM PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 263 UNITED KINGDOM PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 264 UNITED KINGDOM FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 265 UNITED KINGDOM LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 266 UNITED KINGDOM STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 267 UNITED KINGDOM COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 268 UNITED KINGDOM FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 269 UNITED KINGDOM BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 270 UNITED KINGDOM PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 271 UNITED KINGDOM ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 272 UNITED KINGDOM ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 273 UNITED KINGDOM NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 274 UNITED KINGDOM NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 275 UNITED KINGDOM ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 276 UNITED KINGDOM TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 277 UNITED KINGDOM ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 278 UNITED KINGDOM ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 279 UNITED KINGDOM SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 280 UNITED KINGDOM SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 281 UNITED KINGDOM TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 282 UNITED KINGDOM ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 283 UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 284 UNITED KINGDOM NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 285 UNITED KINGDOM ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 286 UNITED KINGDOM SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 287 UNITED KINGDOM FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 288 UNITED KINGDOM PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 289 UNITED KINGDOM THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 290 UNITED KINGDOM NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 291 UNITED KINGDOM BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 292 UNITED KINGDOM CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 293 UNITED KINGDOM PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 294 UNITED KINGDOM ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 295 UNITED KINGDOM SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 296 UNITED KINGDOM HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 297 UNITED KINGDOM DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 298 UNITED KINGDOM NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 299 UNITED KINGDOM GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 300 UNITED KINGDOM DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 301 UNITED KINGDOM OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 302 UNITED KINGDOM BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 303 UNITED KINGDOM ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 304 UNITED KINGDOM INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 305 UNITED KINGDOM TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 306 UNITED KINGDOM BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 307 UNITED KINGDOM BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 308 UNITED KINGDOM BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 309 UNITED KINGDOM BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 310 UNITED KINGDOM RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 311 ITALY BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 312 ITALY ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 313 ITALY DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 314 ITALY ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 315 ITALY ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 316 ITALY BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 317 ITALY CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 318 ITALY DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 319 ITALY ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 320 ITALY CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 321 ITALY HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 322 ITALY STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 323 ITALY SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 324 ITALY ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 325 ITALY PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 326 ITALY ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 327 ITALY THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 328 ITALY OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 329 ITALY ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 330 ITALY PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 331 ITALY PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 332 ITALY FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 333 ITALY LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 334 ITALY STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 335 ITALY COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 336 ITALY FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 337 ITALY BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 338 ITALY PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 339 ITALY ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 340 ITALY ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 341 ITALY NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 342 ITALY NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 343 ITALY ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 344 ITALY TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 345 ITALY ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 346 ITALY ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 347 ITALY SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 348 ITALY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 349 ITALY TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 350 ITALY ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 351 ITALY MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 352 ITALY NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 353 ITALY ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 354 ITALY SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 355 ITALY FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 356 ITALY PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 357 ITALY THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 358 ITALY NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 359 ITALY BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 360 ITALY CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 361 ITALY PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 362 ITALY ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 363 ITALY SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 364 ITALY HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 365 ITALY DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 366 ITALY NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 367 ITALY GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 368 ITALY DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 369 ITALY OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 370 ITALY BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 371 ITALY ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 372 ITALY INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 373 ITALY TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 374 ITALY BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 375 ITALY BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 376 ITALY BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 377 ITALY BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 378 ITALY RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 379 FRANCE BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 380 FRANCE ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 381 FRANCE DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 382 FRANCE ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 383 FRANCE ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 384 FRANCE BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 385 FRANCE CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 386 FRANCE DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 387 FRANCE ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 388 FRANCE CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 389 FRANCE HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 390 FRANCE STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 391 FRANCE SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 392 FRANCE ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 393 FRANCE PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 394 FRANCE ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 395 FRANCE THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 396 FRANCE OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 397 FRANCE ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 398 FRANCE PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 399 FRANCE PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 400 FRANCE FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 401 FRANCE LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 402 FRANCE STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 403 FRANCE COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 404 FRANCE FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 405 FRANCE BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 406 FRANCE PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 407 FRANCE ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 408 FRANCE ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 409 FRANCE NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 410 FRANCE NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 411 FRANCE ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 412 FRANCE TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 413 FRANCE ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 414 FRANCE ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 415 FRANCE SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 416 FRANCE SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 417 FRANCE TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 418 FRANCE ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 419 FRANCE MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 420 FRANCE NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 421 FRANCE ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 422 FRANCE SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 423 FRANCE FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 424 FRANCE PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 425 FRANCE THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 426 FRANCE NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 427 FRANCE BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 428 FRANCE CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 429 FRANCE PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 430 FRANCE ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 431 FRANCE SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 432 FRANCE HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 433 FRANCE DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 434 FRANCE NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 435 FRANCE GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 436 FRANCE DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 437 FRANCE OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 438 FRANCE BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 439 FRANCE ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 440 FRANCE INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 441 FRANCE TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 442 FRANCE BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 443 FRANCE BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 444 FRANCE BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 445 FRANCE BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 446 FRANCE RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 447 SPAIN BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 448 SPAIN ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 449 SPAIN DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 450 SPAIN ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 451 SPAIN ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 452 SPAIN BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 453 SPAIN CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 454 SPAIN DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 455 SPAIN ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 456 SPAIN CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 457 SPAIN HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 458 SPAIN STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 459 SPAIN SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 460 SPAIN ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 461 SPAIN PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 462 SPAIN ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 463 SPAIN THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 464 SPAIN OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 465 SPAIN ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 466 SPAIN PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 467 SPAIN PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 468 SPAIN FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 469 SPAIN LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 470 SPAIN STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 471 SPAIN COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 472 SPAIN FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 473 SPAIN BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 474 SPAIN PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 475 SPAIN ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 476 SPAIN ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 477 SPAIN NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 478 SPAIN NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 479 SPAIN ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 480 SPAIN TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 481 SPAIN ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 482 SPAIN ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 483 SPAIN SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 484 SPAIN SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 485 SPAIN TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 486 SPAIN ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 487 SPAIN MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 488 SPAIN NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 489 SPAIN ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 490 SPAIN SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 491 SPAIN FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 492 SPAIN PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 493 SPAIN THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 494 SPAIN NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 495 SPAIN BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 496 SPAIN CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 497 SPAIN PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 498 SPAIN ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 499 SPAIN SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 500 SPAIN HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 501 SPAIN DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 502 SPAIN NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 503 SPAIN GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 504 SPAIN DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 505 SPAIN OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 506 SPAIN BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 507 SPAIN ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 508 SPAIN INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 509 SPAIN TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 510 SPAIN BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 511 SPAIN BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 512 SPAIN BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 513 SPAIN BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 514 SPAIN RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 515 TURKEY BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 516 TURKEY ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 517 TURKEY DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 518 TURKEY ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 519 TURKEY ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 520 TURKEY BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 521 TURKEY CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 522 TURKEY DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 523 TURKEY ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 524 TURKEY CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 525 TURKEY HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 526 TURKEY STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 527 TURKEY SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 528 TURKEY ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 529 TURKEY PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 530 TURKEY ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 531 TURKEY THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 532 TURKEY OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 533 TURKEY ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 534 TURKEY PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 535 TURKEY PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 536 TURKEY FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 537 TURKEY LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 538 TURKEY STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 539 TURKEY COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 540 TURKEY FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 541 TURKEY BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 542 TURKEY PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 543 TURKEY ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 544 TURKEY ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 545 TURKEY NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 546 TURKEY NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 547 TURKEY ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 548 TURKEY TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 549 TURKEY ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 550 TURKEY ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 551 TURKEY SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 552 TURKEY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 553 TURKEY TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 554 TURKEY ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 555 TURKEY MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 556 TURKEY NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 557 TURKEY ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 558 TURKEY SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 559 TURKEY FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 560 TURKEY PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 561 TURKEY THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 562 TURKEY NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 563 TURKEY BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 564 TURKEY CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 565 TURKEY PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 566 TURKEY ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 567 TURKEY SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 568 TURKEY HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 569 TURKEY DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 570 TURKEY NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 571 TURKEY GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 572 TURKEY DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 573 TURKEY OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 574 TURKEY BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 575 TURKEY ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 576 TURKEY INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 577 TURKEY TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 578 TURKEY BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 579 TURKEY BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 580 TURKEY BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 581 TURKEY BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 582 TURKEY RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 583 RUSSIA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 584 RUSSIA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 585 RUSSIA DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 586 RUSSIA ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 587 RUSSIA ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 588 RUSSIA BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 589 RUSSIA CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 590 RUSSIA DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 591 RUSSIA ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 592 RUSSIA CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 593 RUSSIA HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 594 RUSSIA STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 595 RUSSIA SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 596 RUSSIA ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 597 RUSSIA PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 598 RUSSIA ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 599 RUSSIA THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 600 RUSSIA OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 601 RUSSIA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 602 RUSSIA PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 603 RUSSIA PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 604 RUSSIA FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 605 RUSSIA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 606 RUSSIA STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 607 RUSSIA COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 608 RUSSIA FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 609 RUSSIA BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 610 RUSSIA PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 611 RUSSIA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 612 RUSSIA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 613 RUSSIA NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 614 RUSSIA NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 615 RUSSIA ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 616 RUSSIA TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 617 RUSSIA ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 618 RUSSIA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 619 RUSSIA SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 620 RUSSIA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 621 RUSSIA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 622 RUSSIA ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 623 RUSSIA MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 624 RUSSIA NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 625 RUSSIA ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 626 RUSSIA SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 627 RUSSIA FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 628 RUSSIA PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 629 RUSSIA THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 630 RUSSIA NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 631 RUSSIA BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 632 RUSSIA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 633 RUSSIA PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 634 RUSSIA ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 635 RUSSIA SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 636 RUSSIA HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 637 RUSSIA DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 638 RUSSIA NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 639 RUSSIA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 640 RUSSIA DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 641 RUSSIA OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 642 RUSSIA BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 643 RUSSIA ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 644 RUSSIA INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 645 RUSSIA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 646 RUSSIA BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 647 RUSSIA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 648 RUSSIA BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 649 RUSSIA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 650 RUSSIA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 651 SWITZERLAND BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 652 SWITZERLAND ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 653 SWITZERLAND DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 654 SWITZERLAND ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 655 SWITZERLAND ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 656 SWITZERLAND BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 657 SWITZERLAND CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 658 SWITZERLAND DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 659 SWITZERLAND ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 660 SWITZERLAND CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 661 SWITZERLAND HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 662 SWITZERLAND STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 663 SWITZERLAND SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 664 SWITZERLAND ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 665 SWITZERLAND PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 666 SWITZERLAND ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 667 SWITZERLAND THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 668 SWITZERLAND OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 669 SWITZERLAND ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 670 SWITZERLAND PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 671 SWITZERLAND PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 672 SWITZERLAND FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 673 SWITZERLAND LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 674 SWITZERLAND STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 675 SWITZERLAND COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 676 SWITZERLAND FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 677 SWITZERLAND BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 678 SWITZERLAND PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 679 SWITZERLAND ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 680 SWITZERLAND ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 681 SWITZERLAND NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 682 SWITZERLAND NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 683 SWITZERLAND ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 684 SWITZERLAND TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 685 SWITZERLAND ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 686 SWITZERLAND ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 687 SWITZERLAND SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 688 SWITZERLAND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 689 SWITZERLAND TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 690 SWITZERLAND ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 691 SWITZERLAND MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 692 SWITZERLAND NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 693 SWITZERLAND ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 694 SWITZERLAND SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 695 SWITZERLAND FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 696 SWITZERLAND PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 697 SWITZERLAND THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 698 SWITZERLAND NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 699 SWITZERLAND BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 700 SWITZERLAND CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 701 SWITZERLAND PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 702 SWITZERLAND ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 703 SWITZERLAND SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 704 SWITZERLAND HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 705 SWITZERLAND DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 706 SWITZERLAND NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 707 SWITZERLAND GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 708 SWITZERLAND DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 709 SWITZERLAND OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 710 SWITZERLAND BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 711 SWITZERLAND ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 712 SWITZERLAND INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 713 SWITZERLAND TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 714 SWITZERLAND BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 715 SWITZERLAND BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 716 SWITZERLAND BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 717 SWITZERLAND BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 718 SWITZERLAND RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 719 NETHERLANDS BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 720 NETHERLANDS ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 721 NETHERLANDS DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 722 NETHERLANDS ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 723 NETHERLANDS ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 724 NETHERLANDS BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 725 NETHERLANDS CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 726 NETHERLANDS DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 727 NETHERLANDS ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 728 NETHERLANDS CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 729 NETHERLANDS HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 730 NETHERLANDS STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 731 NETHERLANDS SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 732 NETHERLANDS ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 733 NETHERLANDS PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 734 NETHERLANDS ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 735 NETHERLANDS THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 736 NETHERLANDS OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 737 NETHERLANDS ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 738 NETHERLANDS PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 739 NETHERLANDS PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 740 NETHERLANDS FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 741 NETHERLANDS LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 742 NETHERLANDS STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 743 NETHERLANDS COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 744 NETHERLANDS FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 745 NETHERLANDS BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 746 NETHERLANDS PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 747 NETHERLANDS ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 748 NETHERLANDS ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 749 NETHERLANDS NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 750 NETHERLANDS NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 751 NETHERLANDS ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 752 NETHERLANDS TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 753 NETHERLANDS ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 754 NETHERLANDS ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 755 NETHERLANDS SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 756 NETHERLANDS SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 757 NETHERLANDS TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 758 NETHERLANDS ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 759 NETHERLANDS MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 760 NETHERLANDS NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 761 NETHERLANDS ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 762 NETHERLANDS SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 763 NETHERLANDS FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 764 NETHERLANDS PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 765 NETHERLANDS THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 766 NETHERLANDS NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 767 NETHERLANDS BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 768 NETHERLANDS CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 769 NETHERLANDS PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 770 NETHERLANDS ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 771 NETHERLANDS SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 772 NETHERLANDS HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 773 NETHERLANDS DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 774 NETHERLANDS NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 775 NETHERLANDS GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 776 NETHERLANDS DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 777 NETHERLANDS OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 778 NETHERLANDS BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 779 NETHERLANDS ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 780 NETHERLANDS INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 781 NETHERLANDS TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 782 NETHERLANDS BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 783 NETHERLANDS BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 784 NETHERLANDS BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 785 NETHERLANDS BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 786 NETHERLANDS RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 787 BELGIUM BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 788 BELGIUM ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 789 BELGIUM DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 790 BELGIUM ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 791 BELGIUM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 792 BELGIUM BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 793 BELGIUM CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 794 BELGIUM DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 795 BELGIUM ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 796 BELGIUM CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 797 BELGIUM HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 798 BELGIUM STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 799 BELGIUM SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 800 BELGIUM ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 801 BELGIUM PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 802 BELGIUM ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 803 BELGIUM THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 804 BELGIUM OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 805 BELGIUM ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 806 BELGIUM PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 807 BELGIUM PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 808 BELGIUM FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 809 BELGIUM LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 810 BELGIUM STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 811 BELGIUM COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 812 BELGIUM FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 813 BELGIUM BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 814 BELGIUM PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 815 BELGIUM ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 816 BELGIUM ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 817 BELGIUM NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 818 BELGIUM NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 819 BELGIUM ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 820 BELGIUM TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 821 BELGIUM ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 822 BELGIUM ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 823 BELGIUM SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 824 BELGIUM SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 825 BELGIUM TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 826 BELGIUM ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 827 BELGIUM MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 828 BELGIUM NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 829 BELGIUM ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 830 BELGIUM SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 831 BELGIUM FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 832 BELGIUM PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 833 BELGIUM THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 834 BELGIUM NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 835 BELGIUM BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 836 BELGIUM CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 837 BELGIUM PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 838 BELGIUM ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 839 BELGIUM SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 840 BELGIUM HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 841 BELGIUM DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 842 BELGIUM NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 843 BELGIUM GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 844 BELGIUM DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 845 BELGIUM OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 846 BELGIUM BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 847 BELGIUM ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 848 BELGIUM INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 849 BELGIUM TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 850 BELGIUM BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 851 BELGIUM BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 852 BELGIUM BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 853 BELGIUM BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 854 BELGIUM RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 855 SWEDEN BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 856 SWEDEN ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 857 SWEDEN DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 858 SWEDEN ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 859 SWEDEN ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 860 SWEDEN BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 861 SWEDEN CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 862 SWEDEN DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 863 SWEDEN ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 864 SWEDEN CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 865 SWEDEN HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 866 SWEDEN STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 867 SWEDEN SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 868 SWEDEN ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 869 SWEDEN PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 870 SWEDEN ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 871 SWEDEN THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 872 SWEDEN OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 873 SWEDEN ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 874 SWEDEN PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 875 SWEDEN PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 876 SWEDEN FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 877 SWEDEN LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 878 SWEDEN STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 879 SWEDEN COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 880 SWEDEN FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 881 SWEDEN BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 882 SWEDEN PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 883 SWEDEN ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 884 SWEDEN ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 885 SWEDEN NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 886 SWEDEN NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 887 SWEDEN ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 888 SWEDEN TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 889 SWEDEN ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 890 SWEDEN ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 891 SWEDEN SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 892 SWEDEN SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 893 SWEDEN TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 894 SWEDEN ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 895 SWEDEN MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 896 SWEDEN NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 897 SWEDEN ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 898 SWEDEN SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 899 SWEDEN FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 900 SWEDEN PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 901 SWEDEN THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 902 SWEDEN NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 903 SWEDEN BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 904 SWEDEN CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 905 SWEDEN PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 906 SWEDEN ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 907 SWEDEN SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 908 SWEDEN HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 909 SWEDEN DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 910 SWEDEN NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 911 SWEDEN GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 912 SWEDEN DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 913 SWEDEN OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 914 SWEDEN BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 915 SWEDEN ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 916 SWEDEN INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 917 SWEDEN TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 918 SWEDEN BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 919 SWEDEN BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 920 SWEDEN BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 921 SWEDEN BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 922 SWEDEN RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 923 DENMARK BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 924 DENMARK ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 925 DENMARK DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 926 DENMARK ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 927 DENMARK ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 928 DENMARK BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 929 DENMARK CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 930 DENMARK DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 931 DENMARK ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 932 DENMARK CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 933 DENMARK HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 934 DENMARK STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 935 DENMARK SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 936 DENMARK ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 937 DENMARK PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 938 DENMARK ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 939 DENMARK THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 940 DENMARK OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 941 DENMARK ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 942 DENMARK PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 943 DENMARK PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 944 DENMARK FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 945 DENMARK LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 946 DENMARK STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 947 DENMARK COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 948 DENMARK FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 949 DENMARK BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 950 DENMARK PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 951 DENMARK ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 952 DENMARK ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 953 DENMARK NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 954 DENMARK NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 955 DENMARK ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 956 DENMARK TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 957 DENMARK ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 958 DENMARK ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 959 DENMARK SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 960 DENMARK SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 961 DENMARK TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 962 DENMARK ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 963 DENMARK MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 964 DENMARK NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 965 DENMARK ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 966 DENMARK SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 967 DENMARK FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 968 DENMARK PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 969 DENMARK THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 970 DENMARK NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 971 DENMARK BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 972 DENMARK CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 973 DENMARK PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 974 DENMARK ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 975 DENMARK SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 976 DENMARK HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 977 DENMARK DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 978 DENMARK NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 979 DENMARK GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 980 DENMARK DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 981 DENMARK OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 982 DENMARK BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 983 DENMARK ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 984 DENMARK INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 985 DENMARK TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 986 DENMARK BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 987 DENMARK BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 988 DENMARK BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 989 DENMARK BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 990 DENMARK RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 991 NORWAY BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 992 NORWAY ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 993 NORWAY DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 994 NORWAY ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 995 NORWAY ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 996 NORWAY BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 997 NORWAY CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 998 NORWAY DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 999 NORWAY ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1000 NORWAY CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1001 NORWAY HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1002 NORWAY STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1003 NORWAY SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1004 NORWAY ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1005 NORWAY PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1006 NORWAY ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1007 NORWAY THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1008 NORWAY OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1009 NORWAY ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1010 NORWAY PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1011 NORWAY PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1012 NORWAY FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1013 NORWAY LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1014 NORWAY STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1015 NORWAY COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1016 NORWAY FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1017 NORWAY BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1018 NORWAY PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1019 NORWAY ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1020 NORWAY ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1021 NORWAY NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1022 NORWAY NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1023 NORWAY ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1024 NORWAY TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1025 NORWAY ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1026 NORWAY ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1027 NORWAY SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1028 NORWAY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1029 NORWAY TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1030 NORWAY ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1031 NORWAY MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1032 NORWAY NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1033 NORWAY ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1034 NORWAY SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1035 NORWAY FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1036 NORWAY PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1037 NORWAY THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1038 NORWAY NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1039 NORWAY BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 1040 NORWAY CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1041 NORWAY PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1042 NORWAY ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1043 NORWAY SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1044 NORWAY HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1045 NORWAY DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1046 NORWAY NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1047 NORWAY GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1048 NORWAY DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1049 NORWAY OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1050 NORWAY BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 1051 NORWAY ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1052 NORWAY INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1053 NORWAY TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1054 NORWAY BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1055 NORWAY BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 1056 NORWAY BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 1057 NORWAY BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 1058 NORWAY RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1059 FINLAND BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 1060 FINLAND ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1061 FINLAND DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1062 FINLAND ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1063 FINLAND ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1064 FINLAND BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1065 FINLAND CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1066 FINLAND DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1067 FINLAND ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1068 FINLAND CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1069 FINLAND HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1070 FINLAND STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1071 FINLAND SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1072 FINLAND ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1073 FINLAND PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1074 FINLAND ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1075 FINLAND THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1076 FINLAND OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1077 FINLAND ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1078 FINLAND PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1079 FINLAND PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1080 FINLAND FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1081 FINLAND LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1082 FINLAND STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1083 FINLAND COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1084 FINLAND FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1085 FINLAND BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1086 FINLAND PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1087 FINLAND ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1088 FINLAND ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1089 FINLAND NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1090 FINLAND NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1091 FINLAND ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1092 FINLAND TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1093 FINLAND ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1094 FINLAND ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1095 FINLAND SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1096 FINLAND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1097 FINLAND TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1098 FINLAND ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1099 FINLAND MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1100 FINLAND NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1101 FINLAND ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1102 FINLAND SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1103 FINLAND FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1104 FINLAND PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1105 FINLAND THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1106 FINLAND NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1107 FINLAND BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 1108 FINLAND CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1109 FINLAND PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1110 FINLAND ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1111 FINLAND SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1112 FINLAND HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1113 FINLAND DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1114 FINLAND NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1115 FINLAND GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1116 FINLAND DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1117 FINLAND OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1118 FINLAND BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 1119 FINLAND ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1120 FINLAND INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1121 FINLAND TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1122 FINLAND BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1123 FINLAND BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 1124 FINLAND BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 1125 FINLAND BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 1126 FINLAND RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1127 REST OF EUROPE BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
Liste des figures
FIGURE 1 EUROPE BRANDED GENERICS MARKET: SEGMENTATION
FIGURE 2 EUROPE BRANDED GENERICS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE BRANDED GENERICS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE BRANDED GENERICS MARKET: EUROPE VS REGIONAL ANALYSIS
FIGURE 5 EUROPE BRANDED GENERICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE BRANDED GENERICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE BRANDED GENERICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE BRANDED GENERICS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 EXECUTIVE SUMMARY
FIGURE 10 STRATEGIC DECISIONS
FIGURE 11 NINE SEGMENTS COMPRISE THE EUROPE BRANDED GENERICS MARKET, BY DRUG CLASS (2024)
FIGURE 12 EUROPE BRANDED GENERICS MARKET: SEGMENTATION
FIGURE 13 PATENT EXPIRATIONS OF BLOCKBUSTER DRUGS ARE EXPECTED TO DRIVE THE EUROPE BRANDED GENERICS MARKET IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 14 ANTI-HYPERTENSIVE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE BRANDED GENERICS MARKET IN 2025 & 2032
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE EUROPE BRANDED GENERICS MARKET
FIGURE 16 EUROPE BRANDED GENERIC MARKET: BY DRUG CLASS, 2024
FIGURE 17 EUROPE BRANDED GENERIC MARKET: BY DRUG CLASS, 2025 TO 2032 (USD THOUSAND)
FIGURE 18 EUROPE BRANDED GENERIC MARKET: BY DRUG CLASS, CAGR (2025- 2032)
FIGURE 19 EUROPE BRANDED GENERIC MARKET: BY DRUG CLASS, LIFELINE CURVE
FIGURE 20 EUROPE BRANDED GENERICS MARKET: BY APPLICATION, 2024
FIGURE 21 EUROPE BRANDED GENERICS MARKET: BY APPLICATION, 2025 TO 2032 (USD THOUSAND)
FIGURE 22 EUROPE BRANDED GENERICS MARKET: BY APPLICATION, CAGR (2025- 2032)
FIGURE 23 EUROPE BRANDED GENERICS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 24 EUROPE BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, 2024
FIGURE 25 EUROPE BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, 2025 TO 2032 (USD THOUSAND)
FIGURE 26 EUROPE BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2025- 2032)
FIGURE 27 EUROPE BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 28 EUROPE BRANDED GENERICS MARKET: BY PRODUCT TYPE, 2024
FIGURE 29 EUROPE BRANDED GENERICS MARKET: BY PRODUCT TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 30 EUROPE BRANDED GENERICS MARKET: BY PRODUCT TYPE, CAGR (2025- 2032)
FIGURE 31 EUROPE BRANDED GENERICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 32 EUROPE BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, 2024
FIGURE 33 EUROPE BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, 2025 TO 2032 (USD THOUSAND)
FIGURE 34 EUROPE BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, CAGR (2025- 2032)
FIGURE 35 EUROPE BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, LIFELINE CURVE
FIGURE 36 EUROPE BRANDED GENERICS MARKET: BY END USER, 2024
FIGURE 37 EUROPE BRANDED GENERICS MARKET: BY END USER, 2025 TO 2032 (USD THOUSAND)
FIGURE 38 EUROPE BRANDED GENERICS MARKET: BY END USER, CAGR (2025- 2032)
FIGURE 39 EUROPE BRANDED GENERICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 EUROPE BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 41 EUROPE BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, 2025 TO 2032 (USD THOUSAND)
FIGURE 42 EUROPE BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025- 2032)
FIGURE 43 EUROPE BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 EUROPE BRANDED GENERICS MARKET: SNAPSHOT (2024)
FIGURE 45 EUROPE BRANDED GENERICS MARKET: COMPANY SHARE 2024 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
